Wellington Management Group LLP Acquires 15,542 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Wellington Management Group LLP raised its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 3.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 470,191 shares of the company's stock after purchasing an additional 15,542 shares during the period. Wellington Management Group LLP owned 1.02% of Pacira BioSciences worth $8,858,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Renaissance Technologies LLC raised its position in shares of Pacira BioSciences by 0.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,992,601 shares of the company's stock valued at $37,541,000 after buying an additional 13,604 shares in the last quarter. Geode Capital Management LLC raised its position in Pacira BioSciences by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,091,970 shares of the company's stock worth $20,578,000 after purchasing an additional 5,071 shares during the period. Point72 Asset Management L.P. purchased a new position in Pacira BioSciences in the 4th quarter worth $20,266,000. Nuveen Asset Management LLC raised its position in Pacira BioSciences by 109.9% in the 4th quarter. Nuveen Asset Management LLC now owns 625,917 shares of the company's stock worth $11,792,000 after purchasing an additional 327,754 shares during the period. Finally, Northern Trust Corp raised its position in Pacira BioSciences by 30.8% in the 4th quarter. Northern Trust Corp now owns 616,891 shares of the company's stock worth $11,622,000 after purchasing an additional 145,205 shares during the period. 99.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

PCRX has been the topic of a number of analyst reports. HC Wainwright lifted their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Barclays raised their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Finally, Needham & Company LLC cut their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Pacira BioSciences presently has a consensus rating of "Hold" and an average target price of $26.44.

Pacira BioSciences Trading Up 2.2%

Shares of PCRX traded up $0.58 during trading hours on Wednesday, reaching $26.98. 657,185 shares of the company traded hands, compared to its average volume of 970,971. The company's fifty day moving average price is $25.41 and its two-hundred day moving average price is $23.16. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -13.29 and a beta of 0.56. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $31.13.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.